On September 28, 2016 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that safety data for two Phase I studies of lirilumab in combination with nivolumab or ipilimumab conducted by Bristol-Myers Squibb in patients with advanced refractory solid tumors will be presented by Dr. Neil H. Segal, Memorial Sloan-Kettering Cancer Center, in a poster at the ESMO (Free ESMO Whitepaper) 2016 congress (October 7 – 11, 2016) in Copenhagen, Denmark (Press release, Innate Pharma, SEP 28, 2016, View Source [SID:SID1234515479]). Lirilumab is Innate Pharma’s anti-KIR antibody partnered with Bristol-Myers Squibb.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!